JP2014527397A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014527397A5 JP2014527397A5 JP2014516320A JP2014516320A JP2014527397A5 JP 2014527397 A5 JP2014527397 A5 JP 2014527397A5 JP 2014516320 A JP2014516320 A JP 2014516320A JP 2014516320 A JP2014516320 A JP 2014516320A JP 2014527397 A5 JP2014527397 A5 JP 2014527397A5
- Authority
- JP
- Japan
- Prior art keywords
- chokα
- expression level
- patient
- sample
- reference value
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11382211 | 2011-06-20 | ||
| EP11382211.8 | 2011-06-20 | ||
| US201161507833P | 2011-07-14 | 2011-07-14 | |
| US61/507,833 | 2011-07-14 | ||
| EP11382294.4 | 2011-09-16 | ||
| EP11382294 | 2011-09-16 | ||
| PCT/EP2012/061790 WO2012175537A1 (en) | 2011-06-20 | 2012-06-20 | Method for predicting the clinical response to chemotherapy in a subject with cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014527397A JP2014527397A (ja) | 2014-10-16 |
| JP2014527397A5 true JP2014527397A5 (enExample) | 2015-08-13 |
Family
ID=47422050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014516320A Pending JP2014527397A (ja) | 2011-06-20 | 2012-06-20 | 癌患者の化学療法に対する臨床応答を予測する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20150004252A1 (enExample) |
| EP (1) | EP2721174A1 (enExample) |
| JP (1) | JP2014527397A (enExample) |
| KR (1) | KR20140047664A (enExample) |
| CN (1) | CN103687964A (enExample) |
| AU (1) | AU2012274156A1 (enExample) |
| BR (1) | BR112013032857A2 (enExample) |
| CA (1) | CA2840129A1 (enExample) |
| MX (1) | MX2013015286A (enExample) |
| RU (1) | RU2014101492A (enExample) |
| WO (1) | WO2012175537A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017083739A1 (en) * | 2015-11-13 | 2017-05-18 | The Trustees Of Columbia University In The City Of New York | A method for predicting a subject's response to valproic acid therapy |
| WO2017188694A1 (ko) * | 2016-04-25 | 2017-11-02 | 이뮤노메트테라퓨틱스 인코포레이티드 | 질소를 포함하는 헤테로아릴 화합물 및 이의 용도 |
| EP3487857B1 (en) * | 2016-07-25 | 2021-09-01 | Nerviano Medical Sciences S.r.l. | Purine and 3-deazapurine analogues as choline kinase inhibitors |
| US11339447B2 (en) | 2017-03-29 | 2022-05-24 | Crown Bioscience, Inc. (Taicang) | System and method for determining Kareniticin sensitivity on cancer |
| CN107050668B (zh) * | 2017-06-09 | 2020-03-31 | 南京医科大学第一附属医院 | 基于云处理的放疗效果预测方法 |
| EP3502700A1 (en) * | 2017-12-21 | 2019-06-26 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Methods based on the detection of rad51 foci in tumor cells |
| CN116859058A (zh) * | 2023-07-17 | 2023-10-10 | 上海中医药大学 | 一种基于NDR1-Myc互作抗结直肠癌活性分子筛选方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| CA2066428C (en) | 1989-09-08 | 2000-11-28 | Bert Vogelstein | Structural alterations of the egf receptor gene in human gliomas |
| JPH11507535A (ja) | 1995-06-07 | 1999-07-06 | イムクローン システムズ インコーポレイテッド | 腫瘍の成長を抑制する抗体および抗体フラグメント類 |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| ES2237332B1 (es) | 2004-01-14 | 2006-11-01 | Consejo Sup. Investig. Cientificas | Derivados de piridinio y quinolinio. |
| KR101322705B1 (ko) * | 2005-04-13 | 2013-10-29 | 꼰세호 수페리올 인베스띠가시오네스 시엔띠피까스 | 콜린 키나아제 베타를 유도하는 의약 조성물 |
| GB0519405D0 (en) * | 2005-09-23 | 2005-11-02 | Univ Aberdeen | Cancer therapy prognosis and target |
| EP2316970A2 (en) * | 2008-07-04 | 2011-05-04 | Traslational Cancer Drugs Pharma, S.L. | Methods for the treatment and diagnosis of cancer |
| JP5764730B2 (ja) | 2008-09-10 | 2015-08-19 | ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー | １個だけで標識された多種類のプローブを用いるｍＲＮＡ単一分子の画像化 |
| US20100068302A1 (en) | 2008-09-17 | 2010-03-18 | Traslational Cancer Drugs Pharma, S.L. | Methods and compositions for the treatment of cancer |
-
2012
- 2012-06-20 KR KR1020147001560A patent/KR20140047664A/ko not_active Withdrawn
- 2012-06-20 RU RU2014101492/10A patent/RU2014101492A/ru not_active Application Discontinuation
- 2012-06-20 CN CN201280035399.6A patent/CN103687964A/zh active Pending
- 2012-06-20 BR BR112013032857A patent/BR112013032857A2/pt not_active IP Right Cessation
- 2012-06-20 JP JP2014516320A patent/JP2014527397A/ja active Pending
- 2012-06-20 WO PCT/EP2012/061790 patent/WO2012175537A1/en not_active Ceased
- 2012-06-20 US US14/128,369 patent/US20150004252A1/en not_active Abandoned
- 2012-06-20 CA CA2840129A patent/CA2840129A1/en not_active Abandoned
- 2012-06-20 EP EP12730874.0A patent/EP2721174A1/en not_active Withdrawn
- 2012-06-20 AU AU2012274156A patent/AU2012274156A1/en not_active Abandoned
- 2012-06-20 MX MX2013015286A patent/MX2013015286A/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | MicroRNAs: a new key in lung cancer | |
| Yu et al. | NEAT 1: A novel cancer‐related long non‐coding RNA | |
| Chen et al. | Predicting distant metastasis and chemoresistance using plasma miRNAs | |
| Yu et al. | The role of mi RNA s in cutaneous squamous cell carcinoma | |
| Wang et al. | The role of microRNA in cisplatin resistance or sensitivity | |
| Drygin et al. | Targeting the nucleolus for cancer-specific activation of p53 | |
| WO2014172376A3 (en) | Markers of tumor cell response to anti-cancer therapy | |
| Yan et al. | Expression and significance of circulating microRNA-31 in lung cancer patients | |
| Han et al. | mRNA expression and clinical significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 in postoperative patients with non-small cell lung cancer | |
| Li et al. | Clinical significance of blood‑based miRNAs as biomarkers of non‑small cell lung cancer | |
| JP2014533960A5 (enExample) | ||
| Jing et al. | Down-expression of miR-373 predicts poor prognosis of glioma and could be a potential therapeutic target | |
| RU2014101492A (ru) | Способ прогнозирования клинического ответа на химиотерапию у субъекта, имеющего рак | |
| Bai et al. | Establishment of tumor treating fields combined with mild hyperthermia as novel supporting therapy for pancreatic cancer | |
| ES3014982T3 (en) | Novel rna molecule for cancer detection | |
| CN103725779A (zh) | 一种非小细胞肺癌早期诊断血清/血浆miRNA标志物及其应用 | |
| Robinson et al. | The role of exosomes in the pathogenesis of pancreatic ductal adenocarcinoma | |
| Ondracek et al. | Global microRNA expression profiling identifies unique microRNA pattern of radioresistant glioblastoma cells | |
| WO2011153345A3 (en) | A gene expression profile of brca-ness that correlates with responsiveness to chemotherapy and with outcome in cancer patients | |
| RU2013119459A (ru) | Комплекс ipp в качестве маркера лечения эрлотинибом | |
| Fang et al. | The expression of microRNA-340 and cyclin D1 and its relationship with the clinicopathological characteristics and prognosis of lung cancer | |
| Wiemer | Prognostic Circulating MicroRNA Biomarkers in Early‐Stage Non‐Small Cell Lung Cancer: A Role for miR‐150 | |
| Bałan et al. | Disorders noticed during development of pancreatic cancer: potential opportunities for early and effective diagnostics and therapy | |
| EA201501095A1 (ru) | Эффективное лечение нмрл и прогностический клинический маркер чувствительной к лечению опухоли | |
| Patil | Validation of a nomogram for predicting risk of local recurrence for ductal carcinoma in situ |